News
-
-
PRESS RELEASE
Catheter Precision, Inc. Announces the Presentation of the First Clinical Data on LockeT
Catheter Precision, Inc. announces LockeT study data presentation at Western AFib Symposium. CEO highlights safety, effectiveness, cost savings, and same-day discharge benefits. Event features renowned experts in atrial fibrillation field -
PRESS RELEASE
Catheter Precision, Inc. Participates in AF Symposium
Catheter Precision, Inc. to showcase VIVO 3D imaging system and LockeT suture retention device at AF Symposium Boston. Participating alongside major medical device companies including Medtronic, Boston Scientific, Abbott, and Johnson and Johnson. CEO David Jenkins highlights the opportunity to generate leads and interest from a dedicated audience of electrophysiologists -
PRESS RELEASE
Catheter Precision, Inc. (VTAK) Secures New Distributor for VIVO in Turkey
Catheter Precision, Inc. (NYSE American: VTAK) has signed a new distributor for Turkey for its non-invasive 3D localization system, VIVO, expanding its footprint in Eastern Europe. The company's focus on expanding sales territory and utilizing local personnel familiar with regulations helps streamline the approval process. VIVO, a non-invasive 3D imaging system, enables physicians to identify the origin of ventricular arrhythmias pre-procedure, reducing procedure time. For more information on the company and its products, visit www.catheterprecision.com. -
PRESS RELEASE
Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico
Catheter Precision, Inc. (NYSE American: VTAK) announces its participation in the Sequire Investor Summit 2024, showcasing its commitment to advancing the well-being of patients with cardiac arrhythmias. The summit, set to take place on January 23-25, 2024, in San Juan, Puerto Rico, offers a platform for the exchange of opportunities among funds, companies, and investors. With Puerto Rico's favorable tax benefits attracting financial entities and affluent individuals, this event holds promise for impactful discussions and collaborations. For details and registration, visit the official event website. Don't miss Catheter Precision's presentation on February 24 at 3:00 PM. -
PRESS RELEASE
Catheter Precision’s VIVO System Featured in Electrophysiology Publication
Catheter Precision, Inc., a leader in non-invasive 3D mapping for ventricular arrhythmias, announced that their VIVO System was highlighted in a case study by EP Lab Digest, a publication dedicated to electrophysiology. The VIVO System, a non-invasive 3D imaging system, enables physicians to identify the origin of ventricular arrhythmias pre-procedure, streamlining workflow and reducing procedure time. This recognition signifies the value of the work presented and the unique approach taken in the case study. -
PRESS RELEASE
CORRECTION: Catheter Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
Catheter Precision, Inc. announces that its CEO and Chairman, Mr. David Jenkins, has been authorized to purchase up to 500,000 shares of the Company's common stock in open market transactions. Mr. Jenkins expresses his commitment to the Company and its innovative technology for electrophysiology procedures to improve the treatment of cardiac arrhythmias. The Company continues its focus on developing groundbreaking technology and seeking innovations to improve the overall health of patients with cardiac arrhythmias. -
PRESS RELEASE
Cather Precision, Inc.'s (VTAK) Board Authorizes its CEO and Chairman to Make "Open Market" Purchases of Company Shares
Catheter Precision, Inc., a US-based medical device company, announces that its CEO and Chairman, Mr. David Jenkins, has been authorized to purchase up to 500,000 shares of the Company's common stock. Mr. Jenkins expresses confidence in the Company's future and its innovative technology for electrophysiology procedures to improve the treatment of cardiac arrhythmias. The press release highlights the Company's focus on developing groundbreaking technology and its achievements with the FDA-registered LockeT product and VIVO 3D mapping system. The press release also contains a cautionary note regarding forward-looking statements and contact information for media inquiries. -
PRESS RELEASE
CATHETER PRECISION, INC. (VTAK) Reports Unaudited Preliminary Fourth Quarter and Full Year 2023 Results
Catheter Precision, Inc. (VTAK:NYSE/American), a US-based medical device company, announced unaudited preliminary annual and fourth quarter results of 2023. These results included total revenues, cash on hand, total assets, shareholders equity, and preliminary net loss. The company also highlighted key achievements of the year, including sales and clinical personnel onboarding and training, product launches, study enrollments, and intellectual property expansion. CEO David Jenkins expressed optimism for 2024, emphasizing the momentum and market potential of their products. The company cautioned that the results are subject to finalization, internal review, potential adjustments, and external audit, with consideration for potential impact from impairment analysis and future royalties. For more information, please refer to the original press release on accesswire.com. -
PRESS RELEASE
Catheter Precision, Inc. (VTAK) Announces Changes to Executive Management and Board of Directors
Catheter Precision, a US-based medical device company, has announced changes to its executive management and board of directors, including the appointment of Margrit Thomassen as the interim Chief Financial Officer and the naming of David Jenkins as the Chief Executive Officer. The company, focused on electrophysiology products, aims to continue its growth and meet the needs of patients, hospitals, and physicians. The announcement also includes the resignation of Susanne Meline from the Board of Directors and the appointment of John Francis as her replacement. These changes are part of the company's strategic plan for the upcoming year.
